BA
VRTX icon

Bard Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bard Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Hold
350
– – 0.04% 144
2026
Q1 		$156K Hold
350
– – 0.04% 146
2025
Q4 		$159K Buy
+350
New +$151K 0.04% 122

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bard Associates's VRTX Position: Q2 2026 in Review

Bard Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 350 shares worth $174K. The position accounts for 0.04% of the portfolio, ranked #144.

Bard Associates first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bard Associates held 350 shares of Vertex Pharmaceuticals worth $174K as of Q2 2026.
  • Bard Associates left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.04% of Bard Associates's portfolio in Q2 2026, its #144 holding.
  • Bard Associates first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.